Dapsone - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for dapsone and what is the scope of freedom to operate?
Dapsone
is the generic ingredient in two branded drugs marketed by Abbvie, Almirall, Alembic, Amneal, Cosette, Encube, Mylan, Padagis Israel, Taro, Torrent, Trupharma, Zydus Lifesciences, Actavis Llc, Alvogen, Chartwell Rx, Everest Life Sci, Nostrum Labs Inc, Novitium Pharma, and Rising, and is included in twenty-five NDAs. There is one patent protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Dapsone has twenty-three patent family members in fifteen countries.
There are eight drug master file entries for dapsone. Twenty-seven suppliers are listed for this compound.
Summary for dapsone
International Patents: | 23 |
US Patents: | 1 |
Tradenames: | 2 |
Applicants: | 19 |
NDAs: | 25 |
Drug Master File Entries: | 8 |
Finished Product Suppliers / Packagers: | 27 |
Raw Ingredient (Bulk) Api Vendors: | 151 |
Clinical Trials: | 88 |
Patent Applications: | 9,475 |
Drug Prices: | Drug price trends for dapsone |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for dapsone |
What excipients (inactive ingredients) are in dapsone? | dapsone excipients list |
DailyMed Link: | dapsone at DailyMed |
Recent Clinical Trials for dapsone
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
All India Institute of Medical Sciences, Bhubaneswar | Phase 4 |
Assiut University | Phase 4 |
Pulmonem Inc. | Phase 3 |
Pharmacology for dapsone
Drug Class | Sulfone |
Medical Subject Heading (MeSH) Categories for dapsone
Anatomical Therapeutic Chemical (ATC) Classes for dapsone
US Patents and Regulatory Information for dapsone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Trupharma | DAPSONE | dapsone | GEL;TOPICAL | 213636-001 | Aug 26, 2024 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Trupharma | DAPSONE | dapsone | GEL;TOPICAL | 213907-001 | Jun 6, 2023 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Amneal | DAPSONE | dapsone | GEL;TOPICAL | 209890-001 | Oct 19, 2023 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Chartwell Rx | DAPSONE | dapsone | TABLET;ORAL | 204074-001 | May 10, 2016 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
Torrent | DAPSONE | dapsone | GEL;TOPICAL | 214722-001 | Feb 10, 2022 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Nostrum Labs Inc | DAPSONE | dapsone | TABLET;ORAL | 203887-002 | May 6, 2016 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
Actavis Llc | DAPSONE | dapsone | TABLET;ORAL | 204380-002 | Mar 23, 2017 | AB | RX | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for dapsone
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Almirall | ACZONE | dapsone | GEL;TOPICAL | 207154-001 | Feb 24, 2016 | 6,060,085 | ⤷ Subscribe |
Abbvie | ACZONE | dapsone | GEL;TOPICAL | 021794-001 | Jul 7, 2005 | 5,863,560 | ⤷ Subscribe |
Almirall | ACZONE | dapsone | GEL;TOPICAL | 207154-001 | Feb 24, 2016 | 6,620,435 | ⤷ Subscribe |
Almirall | ACZONE | dapsone | GEL;TOPICAL | 207154-001 | Feb 24, 2016 | 5,863,560 | ⤷ Subscribe |
Abbvie | ACZONE | dapsone | GEL;TOPICAL | 021794-001 | Jul 7, 2005 | 6,620,435 | ⤷ Subscribe |
Abbvie | ACZONE | dapsone | GEL;TOPICAL | 021794-001 | Jul 7, 2005 | 6,060,085 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for dapsone
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Hungary | E035940 | ⤷ Subscribe | |
Hong Kong | 1214516 | 局部氨苯碸和氨苯碸/阿達帕林組合物及其使用方法 (TOPICAL DAPSONE AND DAPSONE ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF) | ⤷ Subscribe |
Brazil | 112015011673 | composições tópicas de dapsona e dapsona/adapaleno e métodos para uso das mesmas | ⤷ Subscribe |
South Korea | 20150085069 | 국소적 댑손 및 댑손/아다팔렌 조성물 및 이의 사용 방법 (TOPICAL DAPSONE AND DAPSONE/ADAPALENE COMPOSITIONS AND METHODS FOR USE THEREOF) | ⤷ Subscribe |
Spain | 2644342 | ⤷ Subscribe | |
Russian Federation | 2015123207 | КОМПОЗИЦИИ ДЛЯ МЕСТНОГО ПРИМЕНЕНИЯ, СОДЕРЖАЩИЕ ДАПСОН И ДАПСОН/АДАПАЛЕН, И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ | ⤷ Subscribe |
Japan | 6285946 | ⤷ Subscribe | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Dapsone Market Analysis and Financial Projection Experimental
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.